Inclusion Criteria:

- Histologically confirmed sarcoma that is recurrent or refractory to conventional
treatment

- Measurable disease by RECIST criteria

- ECOG performance status < 2 (or Lansky/Karnofsky > 60% for children)

- Life expectancy greater than 3 months

- Adequate organ function

- absolute neutrophil count at least 1,500

- platelets at least 100,000

- bilirubin less than 1.5 x upper limit of normal

- AST and ALT less than 2.5 x upper limit of normal

- creatinine less than 1.5 x upper limit of normal OR creatinine clearance at least 60
ml/min/1.73 m2

- fasting serum cholesterol less than 350

- fasting serum triglycerides less than 400

- PT or INR less than 1.3 x upper limit of normal

- normal urinalysis

- Ability to understand and sign the informed consent document

Exclusion Criteria:

- Prior chemotherapy or radiotherapy within 3 weeks of entering the study (6 weeks for
nitrosoureas or mitomycin C)

- Prior treatment with a tyrosine kinase inhibitor within 10 days of entering the study

- History of pulmonary hypertension or pneumonitis

- Patients may not be receiving other investigational agents

- Prior therapy with rapamycin, rapamycin analogues, or tacrolimus

- Uncontrolled brain metastases

- History of grade 3 or 4 hypersensitivity to macrolide antibiotics

- Concurrent treatment with immunosuppressive agents other than a stable (for more than
2 weeks) dose of corticosteroids

- Uncontrolled intercurrent illness

- Pregnancy or breast feeding

- HIV-positive patients on combination antiretroviral therapy

- Grade 3 or 4 proteinuria